Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:EXC News 2 December 2025 - 1 January 2026

Utilities stocks today: NextEra’s $4 billion share-sale plan keeps XLU under pressure into 2026

Utilities stocks today: NextEra’s $4 billion share-sale plan keeps XLU under pressure into 2026

NEW YORK, January 1, 2026, 1:53 PM ET — Market closed U.S. utilities stocks headed into the New Year on the back foot after NextEra Energy disclosed a $4 billion at-the-market share-sale program, a move that can add supply to the market over time. The Utilities Select Sector SPDR Fund, an exchange-traded fund that tracks a basket of utility stocks, last closed down 0.6% at $42.69. (SEC filing) Why it matters now: utilities are among the most interest-rate-sensitive parts of the equity market because investors often value them for steady cash flows and dividends. When financing costs rise or equity
1 January 2026
·····
Utilities Stocks Outlook for 2026: AI Data Center Demand, Rate Cuts, and the New Power-Grid Investment Cycle

Utilities Stocks Outlook for 2026: AI Data Center Demand, Rate Cuts, and the New Power-Grid Investment Cycle

Dec. 20, 2025 Utilities stocks are having a moment that would’ve been hard to imagine just a few years ago. The sector long known for predictable dividends and regulated earnings is now being pulled into the center of the AI buildout—because none of it runs without electricity. As of Dec. 20, 2025, the utilities story is no longer just “bond-proxy, defensive, yield.” It’s increasingly about load growth, grid reliability, data centers, and a multi-year capital spending wave—with investors trying to decide whether the sector’s recent pullback is a warning sign or an entry point. Below is a detailed roundup of
20 December 2025
········
Pennsylvania Electric Bills Jump After December 1 Rate Hikes: How Much PECO, PPL and Other Utilities Now Charge

Pennsylvania Electric Bills Jump After December 1 Rate Hikes: How Much PECO, PPL and Other Utilities Now Charge

PHILADELPHIA / PITTSBURGH – December 2, 2025 Pennsylvania households are waking up this week to higher electric bills after nearly every state‑regulated utility raised its default supply rate on December 1, just as winter heating season begins. State regulators say the increases are being driven by soaring wholesale power and “capacity” costs on the regional PJM grid, a surge in electricity demand from data centers and electric heating, and the retirement of older power plants. Pennsylvania Public Utility Commission+1 Local TV stations, newspapers and energy analysts across the state — including 6abc in Philadelphia, FOX43 in central Pennsylvania and the
2 December 2025
·

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop